MASSACHUSETTS GENERAL HOSPITAL

Troriluzole met primary endpoint in SCA study, showing significant f-SARA improvements. Biohaven plans to submit an NDA to FDA for all SCA genotypes. Troriluzole demonstrated 50-70% slower disease progression, delaying decline by 1.5-2.2 years. Treatment showed consistent efficacy across 3 years, with a 58% reduction in fall risk.

Troriluzole treatment in SCA patients shows 50-70% slower disease progression, delaying progression by 1.5-2.2 years over 3 years. A responder sensitivity analysis revealed an odds ratio of 4.1 (95% CI: 2.1, 8.1) for untreated vs. troriluzole-treated patients (p < 0.0001). Biohaven plans to submit an NDA to the FDA in Q4 2024 for troriluzole in SCA.

One in three former NFL players believe they have CTE, reporting more brain function issues, depression, and suicidal thoughts, compared to those without such beliefs.

AI in cancer care may aid early diagnosis, reduce radiologist workload, assist in clinical trial recruitment, manage data, and determine imaging responses. However, limitations include privacy, reliability, and cost. AI's broad applications span clinical trial design, treatment response, triaging, imaging, pathology, genomics, and more. AI models like Sybil can predict lung cancer risk from a single low-dose CT scan. Despite potential, human oversight remains crucial due to AI's lack of pathophysiological understanding.

Habener and Mojsov, honored with the Lasker Award, pioneered GLP-1 research, leading to diabetes and obesity drugs like Ozempic. Their work began with studying glucagon and pivoted to fish research, revealing GLP-1's potential. Mojsov's predictions and synthesis methods identified GLP-1's therapeutic effects, later developed by Knudsen into long-lasting treatments. GLP-1 drugs now show broader health benefits, including potential for dementia protection.

Novo Nordisk shares fell 6% after mixed Phase 2 weight-loss drug results; Sanofi presented data supporting tolebrutinib for MS; Lasker Awards given to scientists for GLP-1 weight-loss drug research; Edgewise Therapeutics' heart failure drug shows promising early results; FDA declines to approve Vanda Pharmaceuticals' gastroparesis drug; House Energy and Commerce Committee supports extending pediatric rare disease voucher program.

Black women face higher breast cancer mortality across all tumor subtypes, with risks varying from 17% to 50% higher. Factors beyond tumor biology, including socioeconomic inequality and limited access to quality treatment, contribute to these disparities. Comprehensive interventions are needed to address these inequities.

Tampa General Hospital (TGH) and Mass General Brigham (MGB) expand their affiliation with new programs, including a bone marrow transplant and CAR-T therapy program. They also grow healthcare services for Florida's veterans through Home Base Florida. The collaboration aims to enhance patient care and medical innovation in Florida.

MDA awards $500,000 to MGH's HEALEY ALS Platform Trial, led by Dr. Sabrina Paganoni, to accelerate ALS treatment research.